Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
Tsuchihashi K, Shimokawa H, Takayoshi K, Nio K, Aikawa T, Matsushita Y, Wada I, Arita S, Ariyama H, Kusaba H, Sonoda KH, Akashi K, Baba E. Tsuchihashi K, et al. Among authors: shimokawa h. Medicine (Baltimore). 2017 Oct;96(42):e8285. doi: 10.1097/MD.0000000000008285. Medicine (Baltimore). 2017. PMID: 29049226 Free PMC article.
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Tsuchihashi K, Kusaba H, Yamada Y, Okumura Y, Shimokawa H, Komoda M, Uchino K, Yoshihiro T, Tsuruta N, Hanamura F, Inadomi K, Ito M, Sagara K, Nakano M, Nio K, Arita S, Ariyama H, Kohashi K, Tominaga R, Oda Y, Akashi K, Baba E. Tsuchihashi K, et al. Among authors: shimokawa h. Mol Clin Oncol. 2017 May;6(5):665-668. doi: 10.3892/mco.2017.1197. Epub 2017 Mar 17. Mol Clin Oncol. 2017. PMID: 28515919 Free PMC article.
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Ito M, Kusaba H, Mukaide S, Kishimoto J, Shimokawa H, Tamura S, Makiyama A, Hirano G, Oda H, Shirakawa T, Komoda M, Uchino K, Tanaka R, Mitsugi K, Esaki T, Arita S, Ariyama H, Akashi K, Baba E. Ito M, et al. Among authors: shimokawa h. Anticancer Drugs. 2017 Nov;28(10):1166-1173. doi: 10.1097/CAD.0000000000000562. Anticancer Drugs. 2017. PMID: 28906258
Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer.
Nakano M, Ito M, Tanaka R, Ariyama H, Mitsugi K, Makiyama A, Uchino K, Esaki T, Tsuruta N, Hanamura F, Yamaguchi K, Okumura Y, Sagara K, Takayoshi K, Nio K, Tsuchihashi K, Tamura S, Shimokawa H, Arita S, Miyawaki K, Kusaba H, Akashi K, Baba E. Nakano M, et al. Among authors: shimokawa h. Cancer Sci. 2018 Nov;109(11):3461-3470. doi: 10.1111/cas.13777. Epub 2018 Sep 27. Cancer Sci. 2018. PMID: 30142697 Free PMC article.
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. Yoshihiro T, et al. Among authors: shimokawa h. Int J Clin Oncol. 2019 May;24(5):508-515. doi: 10.1007/s10147-018-01391-w. Epub 2019 Jan 2. Int J Clin Oncol. 2019. PMID: 30604155 Clinical Trial.
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
Ohmura H, Yamaguchi K, Hanamura F, Ito M, Makiyama A, Uchino K, Shimokawa H, Tamura S, Esaki T, Mitsugi K, Shibata Y, Oda H, Tsuchihashi K, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E. Ohmura H, et al. Among authors: shimokawa h. Br J Cancer. 2020 May;122(10):1507-1517. doi: 10.1038/s41416-020-0810-1. Epub 2020 Mar 23. Br J Cancer. 2020. PMID: 32203221 Free PMC article.
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Sakai D, et al. Among authors: shimokawa h. Eur J Cancer. 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32526634 Clinical Trial.
1,132 results